ストックスクリーナーアプリを入手
11.58
6.16%
-0.76
Kalvista Pharmaceuticals Inc (KALV) 最新ニュース
KalVista Pharmaceuticals Inc. (NASDAQ: KALV) Stock Rockets 23%: How To Trade Now? - DRP Journal
KalVista seeks approval for oral HAE treatment in multiple countries - Investing.com
H.C. Wainwright initates KalVista Pharmaceuticals Inc (KALV) rating to a Buy - Knox Daily
KalVista seeks approval for oral HAE treatment in multiple countries By Investing.com - Investing.com Canada
KalVista seeks approval for oral HAE treatment in multiple countries - Investing.com India
KalVista Pharmaceuticals Inc: Buy, Hold, or Sell? Analysts Weigh In Amid Market Challenges - The InvestChronicle
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - BioSpace
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - The Bakersfield Californian
KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema - StockTitan
Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap Up to $10.00 - MarketBeat
Jones Trading Sets $35 Target on Kalvista Pharmaceuticals - Investing.com
KalVista Completes Study On Hereditary Disorder Treatment: Shares Dip - BW Healthcare
KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF) - StockTitan
Kaival Brands’ (KAVL) Stock Surges After Merger Announcement with Delta Corp. - TipRanks
(KALA) Long Term Investment Analysis - Stock Traders Daily
Kaival Brands Innovations Group Inc. (NASDAQ:KAVL) Stock Makes a Big Move: But Why? - DRP Journal
Great Point Partners LLC Takes $15.77 Million Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
KLAC (KLA Corp.) may reap gains as insiders became active recently - Knox Daily
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
Kaival Brands Shares More Than Double on Delta Corp Holdings Merger - MarketWatch
Head-To-Head Review: KalVista Pharmaceuticals (NASDAQ:KALV) vs. Mersana Therapeutics (NASDAQ:MRSN) - Defense World
KAVL’s price-to-sales ratio: Is it a good investment opportunity? - US Post News
What's Going On With Kaival Brands Stock Monday? - Benzinga
Tairen Capital Ltd Trims Stock Position in KLA Co. (NASDAQ:KLAC) - MarketBeat
An analyst sees good growth prospects for Kaltura Inc (KLTR) - SETE News
Edge Capital Group LLC Has $6.13 Million Stock Position in KLA Co. (NASDAQ:KLAC) - Defense World
Calithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.com - Defense World
Texas Permanent School Fund Corp Purchases 2,319 Shares of Kaiser Aluminum Co. (NASDAQ:KALU) - Defense World
(KALV) Long Term Investment Analysis - Stock Traders Daily
Stocks Flashing Renewed Technical Strength: KLA - Investor's Business Daily
KLAC Shares Experience Decline in Value - Knox Daily
Novo Nordisk and NanoVation Inked $600M+ Genetic Medicine Deal - Inside Precision Medicine
Closing Figures Unveiled: KLA Corp. (KLAC) Drop -1.16, Closes at 731.04 - The Dwinnex
Did KLA Corp. (KLAC) perform well in the last session? - US Post News
Bank of New York Mellon Corp Purchases 23,547 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
The Potential Rise in the Price of KalVista Pharmaceuticals Inc (KALV) following insiders activity - Knox Daily
Kaiser Aluminum Co. (NASDAQ:KALU) Short Interest Down 14.6% in August - Defense World
Trading Day Triumph: KalVista Pharmaceuticals Inc (KALV) Ends at 10.57, a -1.86 Surge/Plunge - The Dwinnex
Why KLA (KLAC) Outpaced the Stock Market Today - Yahoo Finance
KLAC stock rated a Hold by TD Cowen - Knox Daily
ANEW Medical announces name change to Klotho Neurosciences - TipRanks
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc. - GlobeNewswire
ANEW MEDICAL, Inc. Announces Name Change to Klotho Neurosciences, Inc. - Yahoo Finance
KLA Co. (NASDAQ:KLAC) Shares Bought by Edgestream Partners L.P. - MarketBeat
Kairos Pharma opens at $4, IPO priced at $4 By Investing.com - Investing.com Australia
First Turn Management LLC Sells 119,880 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Examining KalVista Pharmaceuticals Inc (KALV) stock is warranted - US Post News
KALV Stock Sees Decline of Approximately -18.73% in Last Five Days - Knox Daily
Metric Analysis: KalVista Pharmaceuticals Inc (KALV)’s Key Ratios in the Limelight - The Dwinnex
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Closing Figures Unveiled: KalVista Pharmaceuticals Inc (KALV) Drop -5.56, Closes at 11.21 - The Dwinnex
KalVista Pharmaceuticals Inc (KALV) Stock: A Year of Stock Market Dynamics - The InvestChronicle
KalVista Pharmaceuticals appoints new CFO - Investing.com
KalVista Pharmaceuticals CEO sells shares worth over $89k - Investing.com India
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $89,620.88 in Stock - MarketBeat
KalVista Pharmaceuticals CEO sells shares worth over $89k - Investing.com
KalVista Pharmaceuticals CEO sells shares worth over $89k By Investing.com - Investing.com UK
KalVista Pharmaceuticals Welcomes New CFO for Future Growth - TipRanks
KalVista Pharmaceuticals appoints new CFO By Investing.com - Investing.com Canada
KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference - StockTitan
KalVista Pharmaceuticals Names Brian Piekos Chief Financial Officer - MarketWatch
KalVista Appoints Brian Piekos as Chief Financial Officer - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Receives Overweight Rating from Cantor Fitzgerald - Defense World
KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Research Analysts Offer Predictions for KalVista Pharmaceuticals, Inc.’s FY2026 Earnings (NASDAQ:KALV) - Defense World
Leerink Partnrs Weighs in on KalVista Pharmaceuticals, Inc.'s FY2026 Earnings (NASDAQ:KALV) - MarketBeat
Leerink Partners holds Outperform on Kalvista stock, expects strong peak sales potential - Investing.com
Sebetralstat shows promise for hereditary angioedema treatment - Investing.com
KalVista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Leerink Partners holds Outperform on Kalvista stock, expects strong peak sales potential - Investing.com Canada
KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Sebetralstat shows promise for hereditary angioedema treatment - Investing.com India
KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024 - Business Wire
KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update - citybiz
0.05%
4.86%
大文字化:
|
ボリューム (24 時間):